Perturbation of the heparin/heparin-sulfate interactome of human breast cancer cells modulates pro-tumourigenic effects associated with PI3K/Akt and MAPK/ERK signalling

Thrombosis and Haemostasis

Volumn 109, Issue 6, 2013, Pages 1148-1157

  Chen, Yunliang ^a   Scully, Michael ^a   Dawson, Gloria ^a   Goodwin, Christopher ^a   Xia, Min ^a   Lu, Xinjie ^a   Kakkar, Ajay ^a,b  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer cell; Heparin heparan sulfate interactomes; Tumourigenicity

Indexed keywords

HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEOHEPARAN SULFATE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL ADHESION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DENSITOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GENE; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CULTURE MEDIA, SERUM-FREE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPARIN; HEPARITIN SULFATE; HUMANS; LIGANDS; MAP KINASE SIGNALING SYSTEM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN BINDING; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84878661746     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-12-0935     Document Type: Article

References (44)

1. Sasisekharan R, Shriver Z, Venkataraman G, et al. Roles of heparan-sulfate gly-cosaminoglycans in cancer. Nat Rev Cancer 2002; 2: 521-8.
2. Capila I, Linhardt RJ., Heparin-protein interactions. Angew Chem Int Ed 2002; 41: 390-412.
3. Ori A, Wilkinson MC, Fernig DG. A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J Biol Chem 2011; 286: 19892-19904.
4. Handel TM, Johnson Z, Crown SE, et al. Regulation of protein function by gly-cosaminoglycans- as exemplified by chemokines. Ann Rev Biochem 2005; 74: 385-410.
5. Liu D, Shriver Z, Venkataraman G, et al. Tumour cell surface heparan sulfate as cryptic promoters or inhibitors of tumour growth and metastasis. Proc Natl Acad Sci USA 2002; 99: 568-573.
6. Raman K, Ninomiya M, Nguyen TK. et al. Novel glycosaminoglycan biosyn-thetic inhibitors affect tumour-associated angiogenesis. Biochem Biophys Res Commun 2011; 404: 86-89.
7. Osborne CK, Arteaga CL. Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat 1990; 15: 3-11.
8. Dreyfuss JL, Regatieri C V, Jarrouge TR, et al. Heparan sulfate proteoglycans: structure, protein interactions and cell signalling. An Acad Bras Cienc 2009; 81: 409-429.
9. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microen-vironment and angiogenesis. J Cell Mol Med 2011; 15: 1013-1031.
10. Chen, Y, Leask A, Abraham DJ, et al. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts. Arthritis Rheum 2008; 58: 577-585.
11. Chen, Y, Shi-Wen X, van Beek, et al. Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 2005; 167: 1699-1711.
12. Hamati H F, Britton EL, Carey DJ. Inhibition of proteoglycan synthesis alters extracellular matrix deposition, proliferation, and cytoskeletal organisation of rat aortic smooth muscle cells in culture. J Cell Biol 1989; 108: 2495-2505.
13. Haggerty JG, Bretton RH, Milstone LM. Response of stratified cultures of human keratinocytes to disruption of proteoglycan synthesis by p-nitrophenyl-β-D-xylopyranoside. J Cell Physiol 1994; 158: 39-46.
14. Abe M, Harpel JG, Metz C N, et al. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994; 216: 276-284.
15. Simstein R, Burow M, Parker A, et al. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med 2002; 228: 995-1003.
16. Mackay A, Tamber N, Fenwick K, et al. A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 2009; 118: 481-498.
17. Furue MK, Na J, Jackson JP, et al. Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. Proc Natl Acad Sci USA 2008; 105: 13409-13414.
18. Flint N, Cove FL, Evans GS. Heparin stimulates the proliferation of imtestinal epithelial cells in primary culture. J Cell Science 1994; 107: 401-411.
19. Hochart H, Jenkins P V, Preston RJ, et al. Concentration-dependent roles for he-parin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood. Thromb Haemost 2008; 99: 570-575.
20. Li HL, Ye KH, Zhang HW, et al. Effect of heparin on apoptosis in human nasop-haryngeal carcinoma CNE2 cells. Cell Res 2001; 11: 311-315.
21. Ishikawa Y, Kitamura M. Inhibition of glomerular cell apoptosis by heparin. Kidney Int 1999; 56: 954-963.
22. Yu MK, Lee DY, Kim YS, et al. Antiangiogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular inter-nality for cancer therapy. Pharm Res 2007: 24: 705-714.
23. Cochran S, Li CP, Ferro V. A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins. Glycoconj J 2009; 26: 577-587.
24. O'Brien N, O'Donovan N, Foley D, et al. Use of a panel of novel genes for differentiating breast cancer from non-breast tissues. Tumour Biol 2007; 28: 312-317.
25. Shehata M, Weidenhofer J, Thamotharampillai K, et al. Tumour protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays. Crit Rev Oncog 2008; 14: 33-55.
26. Ummanni R, Teller S, Junker H, et al. Altered expression of tumour protein D52 regulates apoptosis and migration of prostate cancer cells. Febs J 2008; 275: 5703-5713.
27. Gumireddy K, Li A, Gimotty PA, et al. KLF17 is a negative regulator of epithe-lial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 2009; 11: 1297-1304.
28. van Agthoven T, Veldscholte J, Smid M, et al. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat 2009; 114: 23-30.
29. Yde C W, Gyrd-Hansen M, Lykkesfeldt AE, et al. Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther 2007; 6: 1869-1876.
30. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997; 327: 1-16.
31. McCubrey JA., Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-279.
32. Platet N, Prévostel C, Derocq D, et al. Breast cancer cell invasiveness: correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and -negative cells. Int J Cancer 1998; 75: 750-756.
33. Tan AR, Alexe G, Reiss M. Transforming growth factor-beta signalling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 2009; 115: 453-495.
34. Mulder KM. Role of Ras and Mapks in TGFb signalling. Cytokine Growth Factor Rev 2000; 11: 23-35.
35. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
36. Klerk C P, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-2135.
37. Cunningham MS, Preston RJ, O'Donnell JS. Does antithrombotic therapy improve survival in cancer patients? Blood Rev 2009; 23: 129-135.
38. Von Tempelhoff, GF, Harenberg J, Niemann F, et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol 2000; 16: 815-824.
39. Lee AY. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am Soc Hematol Educ Program 2010; 2010: 144-149.
40. Collen A, Smorenburg SM, Peters E, et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000; 60: 6196-6200.
41. Lazo-Langner A, Goss GD, Spaans JN, et al. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007; 5: 729-737.
42. Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight hepa-rin: preclinical evidence. Thromb Haemost 2009; 102: 258-267.
43. Niers TM, Klerk CP, DiNisio M, et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007; 61: 195-207.
44. Castelli R, Porro F, Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med 2004; 9: 205-213.